Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

Phase 2

Recruiting

• Conditions: Node-positive Breast Cancer
• Interventions: Radiation: Ultra-hypofractionated breast/chest wall and regional nodal radiation; Radiation: Hypofractionated radiation

• Registration Number: NCT06559540
• Lead Sponsor: Washington University School of Medicine

Brief Summary

In breast cancer patients with nodal involvement, numerous studies have demonstrated that adjuvant radiation therapy reduces the risk of local recurrence, regional recurrence, and distant metastases, in addition to improving survival. The dose and fractionation for adjuvant breast radiation therapy has evolved over time, as novel schedules have been compared...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2024-08-14
• Study First Submitted QC: 2024-08-14
• Study First Posted: 2024-08-19
• Study Start: 2024-08-27
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-10
• Last Update Posted: 2024-10-14
• Primary Completion: 2034-04-30
• Study Completion: 2034-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 220

Inclusion Criteria

• Histologically confirmed invasive carcinoma of the breast. Metaplastic breast cancer is allowed.
• AJCC 8th Edition Stage: cT1-3 primary tumor. cN1-2 or pN1-2.
• Biopsy-proven involved axillary node(s) (either at baseline and/or at time of surgery).
• Undergone either partial mastectomy (with negative final histologic margins (defined as no tumor on ink, after initial surgery or re-excision)) or mastectomy (with negative histologic margins defined as tumor (either invasive or in situ disease) > 2 mm from the final margin).
• Nodal surgery with either sentinel lymph node biopsy or axillary lymph node dissection. Effort to recover the original biopsy-proven node should be performed at time of surgery.
• Systemic therapy (chemotherapy and/or endocrine therapy) should be administered as per standard of care and recommendation of medical oncology. Neoadjuvant and/or adjuvant systemic therapy is allowed. Concurrent endocrine therapy, anti-HER2 therapy, and immunotherapy during RT is allowed.
• All radiation therapy must be planned to be delivered at BJH or a Siteman satellite location.
• Female.
• Age ≥ 18 years at diagnosis.
• ECOG Zubrod performance status 0 or 1.
• English speaker.
• Able to understand and willing to sign IRB-approved written informed consent document.

Read More

Exclusion Criteria

• Presence of distant metastases.
• Diagnosis of nonepithelial breast malignancies such as sarcoma or lymphoma.
• Diagnosis of bilateral breast cancer.
• AJCC cT4 disease, pT4 disease, or any skin involvement on exam or pathology, including dermal LVSI.
• Presence of palpable or radiographically suspicious supraclavicular, infraclavicular, or internal mammary nodes.
• Prior radiation therapy which would have any overlap with current radiation therapy plan.
• Diagnosis of prior breast cancer or diagnosis of current breast cancer more than one year prior to enrollment.
• Diagnosis of systemic lupus erythematosis, scleroderma, or dermatomyositis.
• Diagnosis of a coexisting medical condition which limits life expectancy to < 2 years.
• Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational treatment. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
• Time between last breast cancer therapy (either surgery or chemotherapy) to RT simulation is greater than 8 weeks.
• Planning to undergo concurrent chemotherapy.
• Pregnancy, which will be excluded prior to simulation.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ultra-hypofractionated breast/chest wall and regional nodal radiation (SWIFT RT)	Ultra-hypofractionated breast/chest wall and regional nodal radiation	Breast/chest wall and regional nodal radiation (2600 cGy in 5 fractions over 1-2 weeks).
Hypofractionated radiation (RT)	Hypofractionated radiation	Breast/chest wall and regional nodal radiation (4256 cGy in 16 fractions over 3-4 weeks).

Primary Outcome Measures

Name	Time	Method
Proportion of patients who are free of serious treatment related late toxicity.	Day 91 through 5 year follow-up (estimated to be 5 years and 1 month)	Toxicities of concern may include lymphedema, radiation pneumonitis, brachial plexopathy, rib fracture, cardiac disease, and breast/chest wall fibrosis.

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States